The
Global Microbubbles/Ultrasound
Contrast Agents Market will grow at a CAGR of 25.2% from 2018 to 2024 to reach USD
1,584.5 million by 2024, according to the latest publication from Meticulous
Research®.
The field of ultrasound contrast imaging has been
literally bursting since the last decade. The advancement in ultrasound
technologies over the last decade have resulted in widespread usage of
ultrasound contrast imaging for clinical applications. This technology is
preferred by most researchers due to low-cost, convenience, and real-time
capability. In addition, as compared to imaging modalities, ultrasound imaging
has good temporal resolution, quantitative data, real-time practice,
noninvasiveness, relatively inexpensive, and no ionizing radiation. Also, it
was reported by researchers that they help to sharp the image, improve the
reliability of the scan, and reduce the need for unnecessary downstream
testing. They found to be safe, convenient, completely radiation-free, and
versatile. Owing to all these benefits, researchers are trying to use them for
diagnostic imaging and other therapeutic areas.
For
detail information visit on our web-site
The global microbubbles/ultrasound contrast agents market
is driven by various factors such as advancement in ultrasound technologies,
benefits of ultrasound over alternative technologies, increase in demand for
diagnostics & image guided procedures, favorable reimbursement policies for
contrast enhanced procedures in the U.S., and growing aging population and
subsequent rise in the prevalence of chronic diseases. In addition, rising
research activities related to microbubbles/ultrasound contrast agents and
emerging economies in the Asia Pacific region provides significant
opportunities for various stakeholders in this market.
The global microbubbles/ultrasound contrast agents market
studied in this report is majorly segmented on the basis of therapeutic area
(cardiovascular diseases, renal and associated diseases, and others),
application (molecular imaging, gene therapy, drug delivery, and stem cells
delivery), and geography.
The key players analyzed in the microbubble/ultrasound
contrast agents market are Lantheus Holdings, Inc. (U.S.), Bracco (Italy), GE
Healthcare (U.S.), Daiichi Sankyo Company, Limited (Japan), and nanoPET Pharma
GmbH (Germany).
For detail analysis and market values, download free sample
report @
| Contact
– Khushal Bombe khushal@meticulousresearch.com Office No-402, 4th Floor, Pushpak Business Hub, Wakad, Pimpri-Chinchwad, 411057 India. Direct Lines: +1-646-781-8004 (North America) +91 744-7780008 (Asia-Pacific) |
No comments:
Post a Comment